Long-Term Survival With Pembrolizumab Re-administration After Pseudo-Progression With Immune-Related...
Long-Term Survival With Pembrolizumab Re-administration After Pseudo-Progression With Immune-Related Interstitial Lung Disease in a Patient With Non-small Cell Lung Cancer
About this item
Full title
Author / Creator
Publisher
Palo Alto (CA): Cureus
Journal title
Language
English
Formats
Publication information
Publisher
Palo Alto (CA): Cureus
Subjects
More information
Scope and Contents
Contents
Immune checkpoint inhibitors may cause specific immune-related reactions, such as pseudo-progression. In particular, malignant pleural effusion tends to worsen due to this phenomenon. However, the appropriate management in such cases is unclear.
We report a 73-year-old man with advanced lung adenocarcinoma and malignant pleural effusion who deve...
Alternative Titles
Full title
Long-Term Survival With Pembrolizumab Re-administration After Pseudo-Progression With Immune-Related Interstitial Lung Disease in a Patient With Non-small Cell Lung Cancer
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8338124
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8338124
Other Identifiers
ISSN
2168-8184
E-ISSN
2168-8184
DOI
10.7759/cureus.16177
